Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer
Immunotherapy using cytotoxic Vγ9Vδ2 T cells is gaining momentum as a novel therapeutic approach for the treatment of solid and haematological malignancies. Vγ9Vδ2 T cells localise to breast cancer lesions in the bone and multiple Vγ9Vδ2 T cell infusions decrease tumour burden and lung metastases. ZOL pre-treatment potentiates the anti-cancer efficacy of Vγ9Vδ2 T cells and decreases tumour-associated bone loss. Adoptive transfer of Vγ9Vδ2 T cells in combination with ZOL may be beneficial in patients with advanced breast cancer.